25 XP   0   0   10

Evogene
Buy, Hold or Sell?

Let's analyse Evogene together

PenkeI guess you are interested in Evogene. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Evogene. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Evogene

I send you an email if I find something interesting about Evogene.

Quick analysis of Evogene (30 sec.)










What can you expect buying and holding a share of Evogene? (30 sec.)

How much money do you get?

How much money do you get?
ILA0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
ILA213.96
Expected worth in 1 year
ILA168.42
How sure are you?
15.0%

+ What do you gain per year?

Total Gains per Share
ILA-45.54
Return On Investment
-17.4%

For what price can you sell your share?

Current Price per Share
ILA261.20
Expected price per share
ILA189.30 - ILA268.10
How sure are you?
50%

1. Valuation of Evogene (5 min.)




Live pricePrice per Share (EOD)

ILA261.20

Intrinsic Value Per Share

ILA-1,026.82 - ILA-1,157.65

Total Value Per Share

ILA-812.86 - ILA-943.69

2. Growth of Evogene (5 min.)




Is Evogene growing?

Current yearPrevious yearGrowGrow %
How rich?$28.6m$43.2m-$12.2m-39.5%

How much money is Evogene making?

Current yearPrevious yearGrowGrow %
Making money-$5.9m-$6.6m$689.4k11.6%
Net Profit Margin-825.0%-2,044.3%--

How much money comes from the company's main activities?

3. Financial Health of Evogene (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#522 / 1010

Most Revenue
#470 / 1010

Most Profit
#464 / 1010

Most Efficient
#785 / 1010

What can you expect buying and holding a share of Evogene? (5 min.)

Welcome investor! Evogene's management wants to use your money to grow the business. In return you get a share of Evogene.

What can you expect buying and holding a share of Evogene?

First you should know what it really means to hold a share of Evogene. And how you can make/lose money.

Speculation

The Price per Share of Evogene is ILA261.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Evogene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Evogene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA213.96. Based on the TTM, the Book Value Change Per Share is ILA-11.38 per quarter. Based on the YOY, the Book Value Change Per Share is ILA-53.39 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Evogene.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per Share
Usd Eps-0.130.0%-0.120.0%-0.13-0.1%-0.120.0%-0.080.0%
Usd Book Value Change Per Share-0.14-0.1%-0.030.0%-0.14-0.1%-0.020.0%-0.050.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.14-0.1%-0.030.0%-0.14-0.1%-0.020.0%-0.050.0%
Usd Price Per Share0.79-0.76-0.79-1.66-4.35-
Price to Earnings Ratio-1.51--1.64--1.67--3.66--3.78-
Price-to-Total Gains Ratio-5.57-4.34--6.07-8.20--76.99-
Price to Book Ratio1.39-1.26-0.92-1.55-2.58-
Price-to-Total Gains Ratio-5.57-4.34--6.07-8.20--76.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.6913964
Number of shares1446
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.03-0.02
Usd Total Gains Per Share-0.03-0.02
Gains per Quarter (1446 shares)-43.57-30.86
Gains per Year (1446 shares)-174.30-123.46
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-174-1840-123-133
20-349-3580-247-256
30-523-5320-370-379
40-697-7060-494-502
50-871-8800-617-625
60-1046-10540-741-748
70-1220-12280-864-871
80-1394-14020-988-994
90-1569-15760-1111-1117
100-1743-17500-1235-1240

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.029.011.00.0%6.033.030.08.7%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%6.034.00.015.0%20.048.01.029.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.069.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%6.034.00.015.0%20.048.01.029.0%

Fundamentals of Evogene

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Fundamental data was last updated by Penke on 2024-04-11 07:16:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Evogene.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Evogene earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • A Net Profit Margin of -1,142.0% means that -11.42 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Evogene:

  • The MRQ is -1,142.0%. The company is making a huge loss. -2
  • The TTM is -825.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,142.0%TTM-825.0%-317.0%
TTM-825.0%YOY-2,044.3%+1,219.3%
TTM-825.0%5Y-2,591.2%+1,766.2%
5Y-2,591.2%10Y-1,498.3%-1,092.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,142.0%-200.1%-941.9%
TTM-825.0%-216.8%-608.2%
YOY-2,044.3%-288.3%-1,756.0%
5Y-2,591.2%-449.1%-2,142.1%
10Y-1,498.3%-605.5%-892.8%
1.1.2. Return on Assets

Shows how efficient Evogene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • -12.9% Return on Assets means that Evogene generated -0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Evogene:

  • The MRQ is -12.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM-11.4%-1.5%
TTM-11.4%YOY-11.1%-0.3%
TTM-11.4%5Y-9.3%-2.1%
5Y-9.3%10Y-6.2%-3.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.9%-13.3%+0.4%
TTM-11.4%-12.8%+1.4%
YOY-11.1%-11.7%+0.6%
5Y-9.3%-13.9%+4.6%
10Y-6.2%-15.7%+9.5%
1.1.3. Return on Equity

Shows how efficient Evogene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • -54.8% Return on Equity means Evogene generated -0.55 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Evogene:

  • The MRQ is -54.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -38.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-54.8%TTM-38.5%-16.3%
TTM-38.5%YOY-18.5%-19.9%
TTM-38.5%5Y-18.2%-20.3%
5Y-18.2%10Y-10.9%-7.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-54.8%-16.9%-37.9%
TTM-38.5%-16.1%-22.4%
YOY-18.5%-15.1%-3.4%
5Y-18.2%-19.3%+1.1%
10Y-10.9%-20.2%+9.3%

1.2. Operating Efficiency of Evogene.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Evogene is operating .

  • Measures how much profit Evogene makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Evogene:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-2,015.3%+2,015.3%
TTM-5Y-2,457.2%+2,457.2%
5Y-2,457.2%10Y-1,429.8%-1,027.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY-2,015.3%-298.2%-1,717.1%
5Y-2,457.2%-492.1%-1,965.1%
10Y-1,429.8%-632.4%-797.4%
1.2.2. Operating Ratio

Measures how efficient Evogene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 14.89 means that the operating costs are 14.89 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Evogene:

  • The MRQ is 14.886. The company is inefficient in keeping operating costs low. -1
  • The TTM is 10.756. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ14.886TTM10.756+4.130
TTM10.756YOY21.737-10.981
TTM10.7565Y30.154-19.399
5Y30.15410Y17.569+12.585
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.8863.231+11.655
TTM10.7563.310+7.446
YOY21.7373.890+17.847
5Y30.1545.739+24.415
10Y17.5697.876+9.693

1.3. Liquidity of Evogene.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Evogene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.96 means the company has 4.96 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Evogene:

  • The MRQ is 4.964. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.668. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.964TTM5.668-0.704
TTM5.668YOY7.100-1.432
TTM5.6685Y8.419-2.751
5Y8.41910Y7.505+0.914
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9643.890+1.074
TTM5.6684.173+1.495
YOY7.1005.344+1.756
5Y8.4196.126+2.293
10Y7.5056.448+1.057
1.3.2. Quick Ratio

Measures if Evogene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • A Quick Ratio of 1.53 means the company can pay off 1.53 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Evogene:

  • The MRQ is 1.533. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.639. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.533TTM1.639-0.106
TTM1.639YOY1.553+0.086
TTM1.6395Y3.081-1.441
5Y3.08110Y3.904-0.824
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5333.514-1.981
TTM1.6393.998-2.359
YOY1.5535.380-3.827
5Y3.0816.105-3.024
10Y3.9046.404-2.500

1.4. Solvency of Evogene.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Evogene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Evogene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.44 means that Evogene assets are financed with 43.9% credit (debt) and the remaining percentage (100% - 43.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Evogene:

  • The MRQ is 0.439. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.415. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.439TTM0.415+0.024
TTM0.415YOY0.279+0.136
TTM0.4155Y0.234+0.180
5Y0.23410Y0.163+0.071
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4390.339+0.100
TTM0.4150.336+0.079
YOY0.2790.271+0.008
5Y0.2340.366-0.132
10Y0.1630.389-0.226
1.4.2. Debt to Equity Ratio

Measures if Evogene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 186.0% means that company has 1.86 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Evogene:

  • The MRQ is 1.860. The company is just able to pay all its debts with equity.
  • The TTM is 1.387. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.860TTM1.387+0.473
TTM1.387YOY0.506+0.881
TTM1.3875Y0.512+0.875
5Y0.51210Y0.307+0.206
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8600.388+1.472
TTM1.3870.402+0.985
YOY0.5060.335+0.171
5Y0.5120.426+0.086
10Y0.3070.461-0.154

2. Market Valuation of Evogene

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Evogene generates.

  • Above 15 is considered overpriced but always compare Evogene to the Biotechnology industry mean.
  • A PE ratio of -1.51 means the investor is paying -1.51 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Evogene:

  • The EOD is -1.326. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.513. Based on the earnings, the company is expensive. -2
  • The TTM is -1.641. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.326MRQ-1.513+0.187
MRQ-1.513TTM-1.641+0.128
TTM-1.641YOY-1.671+0.030
TTM-1.6415Y-3.655+2.014
5Y-3.65510Y-3.781+0.126
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.326-2.264+0.938
MRQ-1.513-2.629+1.116
TTM-1.641-2.680+1.039
YOY-1.671-4.145+2.474
5Y-3.655-6.257+2.602
10Y-3.781-6.254+2.473
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Evogene:

  • The EOD is -1.456. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.662. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.774. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.456MRQ-1.662+0.205
MRQ-1.662TTM-1.774+0.113
TTM-1.774YOY-1.842+0.068
TTM-1.7745Y-3.128+1.354
5Y-3.12810Y-1.564-1.564
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.456-2.973+1.517
MRQ-1.662-3.333+1.671
TTM-1.774-3.553+1.779
YOY-1.842-5.605+3.763
5Y-3.128-8.376+5.248
10Y-1.564-8.865+7.301
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Evogene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.39 means the investor is paying 1.39 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Evogene:

  • The EOD is 1.221. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.393. Based on the equity, the company is underpriced. +1
  • The TTM is 1.259. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.221MRQ1.393-0.172
MRQ1.393TTM1.259+0.133
TTM1.259YOY0.918+0.341
TTM1.2595Y1.553-0.294
5Y1.55310Y2.581-1.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2211.896-0.675
MRQ1.3932.115-0.722
TTM1.2592.093-0.834
YOY0.9182.884-1.966
5Y1.5533.542-1.989
10Y2.5813.916-1.335
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Evogene compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---53.541-11.384-79%-53.3880%-8.064-85%-17.913-67%
Book Value Per Share--213.962231.513-8%323.005-34%382.320-44%533.344-60%
Current Ratio--4.9645.668-12%7.100-30%8.419-41%7.505-34%
Debt To Asset Ratio--0.4390.415+6%0.279+57%0.234+87%0.163+169%
Debt To Equity Ratio--1.8601.387+34%0.506+267%0.512+263%0.307+506%
Dividend Per Share----0%-0%-0%-0%
Eps---49.237-44.528-10%-49.673+1%-44.679-9%-31.335-36%
Free Cash Flow Per Share---44.836-41.700-7%-46.337+3%-43.342-3%-43.342-3%
Free Cash Flow To Equity Per Share---45.933-7.851-83%-28.915-37%-6.911-85%-6.911-85%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.725+38%
Intrinsic Value_10Y_max---1157.647--------
Intrinsic Value_10Y_min---1026.819--------
Intrinsic Value_1Y_max---171.780--------
Intrinsic Value_1Y_min---168.762--------
Intrinsic Value_3Y_max---473.622--------
Intrinsic Value_3Y_min---453.017--------
Intrinsic Value_5Y_max---724.220--------
Intrinsic Value_5Y_min---675.861--------
Market Cap13222805960.000-14%15085743400.00014611149962.500+3%15081946652.500+0%31692970081.500-52%83261533650.750-82%
Net Profit Margin---11.420-8.250-28%-20.443+79%-25.912+127%-14.983+31%
Operating Margin----0%-20.1530%-24.5720%-14.2980%
Operating Ratio--14.88610.756+38%21.737-32%30.154-51%17.569-15%
Pb Ratio1.221-14%1.3931.259+11%0.918+52%1.553-10%2.581-46%
Pe Ratio-1.326+12%-1.513-1.641+8%-1.671+10%-3.655+142%-3.781+150%
Price Per Share261.200-14%298.000288.625+3%297.925+0%626.055-52%1644.728-82%
Price To Free Cash Flow Ratio-1.456+12%-1.662-1.774+7%-1.842+11%-3.128+88%-1.564-6%
Price To Total Gains Ratio-4.879+12%-5.5664.336-228%-6.066+9%8.202-168%-76.988+1283%
Quick Ratio--1.5331.639-6%1.553-1%3.081-50%3.904-61%
Return On Assets---0.129-0.114-12%-0.111-14%-0.093-28%-0.062-52%
Return On Equity---0.548-0.385-30%-0.185-66%-0.182-67%-0.109-80%
Total Gains Per Share---53.541-11.384-79%-53.3880%-8.064-85%-17.913-67%
Usd Book Value--28670864.03231022704.474-8%43282659.789-34%51230840.994-44%71468063.174-60%
Usd Book Value Change Per Share---0.142-0.030-79%-0.1410%-0.021-85%-0.047-67%
Usd Book Value Per Share--0.5660.613-8%0.855-34%1.012-44%1.412-60%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.130-0.118-10%-0.131+1%-0.118-9%-0.083-36%
Usd Free Cash Flow---6008037.779-5587745.002-7%-6209188.603+3%-4646209.219-23%-2323104.610-61%
Usd Free Cash Flow Per Share---0.119-0.110-7%-0.123+3%-0.115-3%-0.115-3%
Usd Free Cash Flow To Equity Per Share---0.122-0.021-83%-0.077-37%-0.018-85%-0.018-85%
Usd Market Cap35000767.376-14%39931962.78038675713.951+3%39921912.789+0%83891291.806-52%220393279.574-82%
Usd Price Per Share0.691-14%0.7890.764+3%0.789+0%1.657-52%4.354-82%
Usd Profit---6597747.027-5966808.107-10%-6656218.198+1%-5986848.227-9%-4198804.809-36%
Usd Revenue--577715.1621409305.152-59%418543.640+38%501652.664+15%1175245.553-51%
Usd Total Gains Per Share---0.142-0.030-79%-0.1410%-0.021-85%-0.047-67%
 EOD+3 -5MRQTTM+3 -29YOY+13 -195Y+5 -2710Y+7 -26

3.2. Fundamental Score

Let's check the fundamental score of Evogene based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.326
Price to Book Ratio (EOD)Between0-11.221
Net Profit Margin (MRQ)Greater than0-11.420
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.533
Current Ratio (MRQ)Greater than14.964
Debt to Asset Ratio (MRQ)Less than10.439
Debt to Equity Ratio (MRQ)Less than11.860
Return on Equity (MRQ)Greater than0.15-0.548
Return on Assets (MRQ)Greater than0.05-0.129
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Evogene based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.865
Ma 20Greater thanMa 50273.075
Ma 50Greater thanMa 100291.384
Ma 100Greater thanMa 200294.045
OpenGreater thanClose246.000
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Interest Expense  61,549141,600203,149-109,88293,267-52,10941,158-335,309-294,150



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets51,101
Total Liabilities22,416
Total Stockholder Equity12,053
 As reported
Total Liabilities 22,416
Total Stockholder Equity+ 12,053
Total Assets = 51,101

Assets

Total Assets51,101
Total Current Assets34,469
Long-term Assets16,632
Total Current Assets
Cash And Cash Equivalents 20,772
Short-term Investments 10,291
Net Receivables 357
Inventory 76
Total Current Assets  (as reported)34,469
Total Current Assets  (calculated)31,496
+/- 2,973
Long-term Assets
Property Plant Equipment 3,435
Intangible Assets 13,169
Long-term Assets  (as reported)16,632
Long-term Assets  (calculated)16,604
+/- 28

Liabilities & Shareholders' Equity

Total Current Liabilities6,944
Long-term Liabilities15,472
Total Stockholder Equity12,053
Total Current Liabilities
Accounts payable 1,785
Total Current Liabilities  (as reported)6,944
Total Current Liabilities  (calculated)1,785
+/- 5,159
Long-term Liabilities
Long term Debt 10,368
Capital Lease Obligations Min Short Term Debt1,138
Long-term Liabilities  (as reported)15,472
Long-term Liabilities  (calculated)11,506
+/- 3,966
Total Stockholder Equity
Total Stockholder Equity (as reported)12,053
Total Stockholder Equity (calculated)0
+/- 12,053
Other
Capital Stock286
Common Stock Shares Outstanding 50,585
Net Invested Capital 22,421
Net Working Capital 27,525
Property Plant and Equipment Gross 25,998



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-31
> Total Assets 
19,524
0
44,896
41,233
10,669
37,420
12,595
33,024
33,948
33,576
43,315
43,440
42,881
42,517
40,583
40,664
42,872
57,165
70,434
67,581
67,890
66,518
65,376
63,549
64,855
63,179
62,004
59,665
137,311
133,964
131,856
129,763
127,586
123,444
119,863
116,366
112,595
109,031
105,934
101,785
95,986
91,900
87,446
83,105
77,602
72,049
68,090
63,666
58,694
57,635
53,454
76,443
71,364
64,645
61,106
65,985
71,915
92,778
87,537
83,389
76,304
66,881
56,662
59,388
56,126
49,475
53,340
57,746
51,101
51,10157,74653,34049,47556,12659,38856,66266,88176,30483,38987,53792,77871,91565,98561,10664,64571,36476,44353,45457,63558,69463,66668,09072,04977,60283,10587,44691,90095,986101,785105,934109,031112,595116,366119,863123,444127,586129,763131,856133,964137,31159,66562,00463,17964,85563,54965,37666,51867,89067,58170,43457,16542,87240,66440,58342,51742,88143,44043,31533,57633,94833,02412,59537,42010,66941,23344,896019,524
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55,814
57,322
0
0
51,919
129,552
0
0
0
0
0
0
0
0
0
0
0
89,490
85,879
81,821
77,842
72,791
67,655
64,083
60,013
55,488
51,841
47,795
53,828
49,027
42,875
39,844
45,392
51,823
72,893
67,867
63,600
56,890
47,628
37,705
40,772
37,751
31,409
35,720
40,555
34,469
34,46940,55535,72031,40937,75140,77237,70547,62856,89063,60067,86772,89351,82345,39239,84442,87549,02753,82847,79551,84155,48860,01364,08367,65572,79177,84281,82185,87989,49000000000000129,55251,9190057,32255,81400000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,913
24,262
0
0
16,655
95,454
0
0
0
0
0
0
0
0
0
0
0
3,236
3,290
5,758
2,457
3,435
5,353
14,731
5,710
5,810
6,588
14,097
16,467
34,748
32,011
31,074
41,494
46,229
38,642
42,755
37,633
32,325
36,013
28,867
31,860
28,980
23,000
20,233
27,331
20,772
20,77227,33120,23323,00028,98031,86028,86736,01332,32537,63342,75538,64246,22941,49431,07432,01134,74816,46714,0976,5885,8105,71014,7315,3533,4352,4575,7583,2903,2360000000000095,45416,6550024,26220,91300000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,260
30,868
0
0
31,684
31,452
0
0
0
0
0
0
0
0
0
0
0
13,137
80,031
73,895
73,399
8,380
60,590
47,540
52,501
22,592
43,420
31,680
35,654
12,128
8,542
7,000
2,000
2,000
31,448
22,609
23,960
21,541
8,545
6,383
6,090
6,375
5,795
13,641
9,896
10,291
10,2919,89613,6415,7956,3756,0906,3838,54521,54123,96022,60931,4482,0002,0007,0008,54212,12835,65431,68043,42022,59252,50147,54060,5908,38073,39973,89580,03113,1370000000000031,45231,6840030,86830,26000000000000000000000000
       Net Receivables 
861
0
978
961
339
1,321
495
115
2,119
781
1,074
866
813
938
1,065
867
2,494
1,945
3,400
2,012
1,528
2,081
4,592
1,941
1,879
2,877
3,426
3,580
2,439
2,907
2,890
2,423
1,859
1,567
1,834
2,046
3,516
2,477
1,622
1,878
1,175
2,511
2,121
1,939
766
1,712
1,812
1,802
675
38
147
147
1,210
2,322
1,770
1,898
2,168
2,803
2,503
2,007
1,166
2,898
2,293
2,657
701
250
178
1,345
357
3571,3451782507012,6572,2932,8981,1662,0072,5032,8032,1681,8981,7702,3221,210147147386751,8021,8121,7127661,9392,1212,5111,1751,8781,6222,4773,5162,0461,8341,5671,8592,4232,8902,9072,4393,5803,4262,8771,8791,9414,5922,0811,5282,0123,4001,9452,4948671,0659388138661,0747812,1191154951,3213399619780861
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
92
172
162
165
566
591
249
113
76
7611324959156616516217292000000000000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,794
5,659
22,615
22,337
21,770
21,262
20,593
20,092
19,885
19,670
19,789
19,414
19,253
18,957
18,616
18,375
18,066
17,620
17,191
16,632
16,63217,19117,62018,06618,37518,61618,95719,25319,41419,78919,67019,88520,09220,59321,26221,77022,33722,6155,6595,7940000000000000000000000000000000000000000000000000
       Property Plant Equipment 
1,691
0
2,950
2,881
742
3,069
993
916
1,359
2,178
2,921
3,254
3,440
3,553
3,671
3,709
4,120
4,333
5,860
5,809
7,138
7,468
7,825
7,597
7,401
7,279
7,572
7,294
7,215
6,929
7,188
8,027
8,812
8,307
8,016
7,943
8,197
7,716
7,354
6,829
6,483
6,017
5,611
5,248
4,792
4,375
3,986
3,632
3,187
5,794
5,659
5,352
5,254
4,920
4,644
4,210
3,944
3,966
3,981
4,322
4,182
4,356
4,303
4,210
4,067
4,091
3,908
3,661
3,435
3,4353,6613,9084,0914,0674,2104,3034,3564,1824,3223,9813,9663,9444,2104,6444,9205,2545,3525,6595,7943,1873,6323,9864,3754,7925,2485,6116,0176,4836,8297,3547,7168,1977,9438,0168,3078,8128,0277,1886,9297,2157,2947,5727,2797,4017,5977,8257,4687,1385,8095,8604,3334,1203,7093,6713,5533,4403,2542,9212,1781,3599169933,0697422,8812,95001,691
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
365
471
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
0
0
0
0
0
0
0
0
0
0
0
00000000000100000000000000000000000000000471365000000000000000000000000000
       Intangible Assets 
0
0
0
0
312
1,083
308
269
261
251
240
228
217
206
194
183
171
160
156
145
134
123
111
100
89
78
67
56
45
33
22
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,255
17,074
0
0
0
16,139
0
0
0
15,207
0
0
0
14,140
0
0
0
13,169
13,16900014,14000015,20700016,13900017,07417,255000000000000000000011223345566778891001111231341451561601711831942062172282402512612693081,0833120000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,050
5,659
22,615
-1
21,770
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000021,770-122,6155,6593,0500000000000000000000000000000000000000000000000000
> Total Liabilities 
3,162
0
3,794
3,488
4,961
19,027
5,574
28,310
24,338
25,089
26,614
24,220
23,542
26,530
20,656
23,186
26,141
24,541
17,579
16,523
19,801
17,519
17,015
15,661
16,596
14,642
14,705
13,257
12,564
10,036
10,028
9,476
11,504
9,756
9,509
8,275
8,843
7,695
8,246
8,503
8,697
8,594
8,111
8,100
8,224
7,702
8,137
7,891
8,388
10,880
10,596
10,309
11,147
9,708
10,132
9,915
15,033
10,674
10,894
12,629
12,884
12,150
11,265
21,090
21,336
20,980
22,231
21,883
22,416
22,41621,88322,23120,98021,33621,09011,26512,15012,88412,62910,89410,67415,0339,91510,1329,70811,14710,30910,59610,8808,3887,8918,1377,7028,2248,1008,1118,5948,6978,5038,2467,6958,8438,2759,5099,75611,5049,47610,02810,03612,56413,25714,70514,64216,59615,66117,01517,51919,80116,52317,57924,54126,14123,18620,65626,53023,54224,22026,61425,08924,33828,3105,57419,0274,9613,4883,79403,162
   > Total Current Liabilities 
3,130
0
3,220
2,954
811
5,434
1,964
19,103
3,282
6,021
5,669
5,546
5,756
6,408
9,372
12,615
16,320
13,224
7,374
7,447
9,080
7,459
8,032
7,760
9,499
8,193
9,046
8,492
8,574
6,537
6,503
6,237
7,919
5,797
5,491
4,743
5,639
4,564
5,445
5,572
5,225
5,668
4,633
4,661
4,664
4,652
4,946
5,062
5,431
5,247
4,713
4,729
5,729
4,488
4,821
4,639
9,676
5,342
5,326
6,541
6,882
6,282
5,541
5,583
5,625
5,356
6,391
6,484
6,944
6,9446,4846,3915,3565,6255,5835,5416,2826,8826,5415,3265,3429,6764,6394,8214,4885,7294,7294,7135,2475,4315,0624,9464,6524,6644,6614,6335,6685,2255,5725,4454,5645,6394,7435,4915,7977,9196,2376,5036,5378,5748,4929,0468,1939,4997,7608,0327,4599,0807,4477,37413,22416,32012,6159,3726,4085,7565,5465,6696,0213,28219,1031,9645,4348112,9543,22003,130
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,891
3,139
0
0
2,945
4,363
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
673
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000673000000000000000000004,3632,945003,1391,89100000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,891
3,139
0
0
2,945
4,363
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
673
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000673000000000000000000004,3632,945003,1391,89100000000000000000000000
       Accounts payable 
795
0
784
893
152
813
1,224
288
403
590
628
587
675
998
601
645
622
584
1,028
998
2,059
975
1,299
1,052
1,416
1,266
1,873
1,461
2,014
1,313
1,488
1,849
1,984
1,181
1,205
1,021
1,771
1,161
1,364
1,071
1,330
778
947
898
1,110
911
1,048
784
1,015
641
748
820
1,001
578
718
701
863
993
1,203
1,850
1,463
1,346
1,324
977
1,036
1,152
1,078
1,176
1,785
1,7851,1761,0781,1521,0369771,3241,3461,4631,8501,2039938637017185781,0018207486411,0157841,0489111,1108989477781,3301,0711,3641,1611,7711,0211,2051,1811,9841,8491,4881,3132,0141,4611,8731,2661,4161,0521,2999752,0599981,0285846226456019986755876285904032881,2248131528937840795
       Other Current Liabilities 
2,335
0
2,404
2,016
659
4,621
741
18,816
2,879
5,431
5,041
4,959
5,074
5,410
8,771
11,970
15,266
12,640
6,346
6,449
7,021
6,484
6,733
6,708
8,083
6,927
7,173
7,031
6,560
5,224
5,015
4,388
5,935
4,616
4,286
3,722
3,868
3,403
4,081
4,501
3,895
4,890
3,686
3,763
3,554
3,741
1,469
1,626
1,400
1,008
457
79
423
408
610
215
4,263
170
170
150
1,783
1,314
1,079
1,398
1,340
0
0
0
0
00001,3401,3981,0791,3141,7831501701704,263215610408423794571,0081,4001,6261,4693,7413,5543,7633,6864,8903,8954,5014,0813,4033,8683,7224,2864,6165,9354,3885,0155,2246,5607,0317,1736,9278,0836,7086,7336,4847,0216,4496,34612,64015,26611,9708,7715,4105,0744,9595,0415,4312,87918,8167414,6216592,0162,40402,335
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,633
5,883
5,580
5,418
5,220
5,311
5,276
5,357
5,332
5,568
6,088
6,002
5,868
5,724
15,507
15,711
15,624
15,840
15,399
15,472
15,47215,39915,84015,62415,71115,5075,7245,8686,0026,0885,5685,3325,3575,2765,3115,2205,4185,5805,8835,6330000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,891
-3,139
0
0
-2,945
-4,363
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,454
3,354
3,233
2,971
2,712
2,616
2,461
2,440
2,350
2,387
2,715
2,669
2,504
2,121
1,927
1,816
1,643
1,479
1,241
1,138
1,1381,2411,4791,6431,8161,9272,1212,5042,6692,7152,3872,3502,4402,4612,6162,7122,9713,2333,3542,45400000000000000000000-4,363-2,94500-3,139-1,89100000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,138
3,209
3,270
3,325
3,485
3,524
3,604
3,694
0
0
0
0
0
0
0
0
0
0
0
0
0000000000003,6943,6043,5243,4853,3253,2703,2093,1380000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,013
4,168
0
0
1,877
963
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000009631,877004,1685,01300000000000000000000000
> Total Stockholder Equity
16,362
16,362
41,102
37,745
5,708
18,393
7,021
4,713
9,610
8,487
16,701
19,220
19,339
15,987
19,927
17,478
16,731
32,624
52,855
51,058
48,089
48,999
48,361
47,888
48,259
48,537
47,299
46,408
124,747
123,928
121,828
120,287
116,082
113,688
110,354
108,091
103,752
101,336
97,688
93,282
87,289
83,306
79,335
75,005
69,378
64,347
59,953
55,502
50,053
46,527
42,588
56,090
50,144
43,976
39,762
44,930
46,045
71,536
66,401
60,692
54,031
45,531
36,949
30,577
27,930
22,089
14,288
18,510
12,053
12,05318,51014,28822,08927,93030,57736,94945,53154,03160,69266,40171,53646,04544,93039,76243,97650,14456,09042,58846,52750,05355,50259,95364,34769,37875,00579,33583,30687,28993,28297,688101,336103,752108,091110,354113,688116,082120,287121,828123,928124,74746,40847,29948,53748,25947,88848,36148,99948,08951,05852,85532,62416,73117,47819,92715,98719,33919,22016,7018,4879,6104,7137,02118,3935,70837,74541,10216,36216,362
   Common Stock
135
0
196
196
43
197
62
70
67
68
79
80
80
80
81
81
82
89
100
100
100
100
100
101
102
102
103
103
137
138
138
139
140
140
140
140
140
140
140
140
141
141
142
142
142
142
142
142
142
142
142
142
142
142
142
177
200
230
231
234
234
234
234
234
235
0
0
0
0
0000235234234234234234231230200177142142142142142142142142142142142142142141141140140140140140140140140139138138137103103102102101100100100100100898281818080807968677062197431961960135
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
83,003
84,138
0
0
86,947
169,469
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000169,46986,9470084,13883,00300000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,640
Cost of Revenue-1,692
Gross Profit3,9483,948
 
Operating Income (+$)
Gross Profit3,948
Operating Expense-32,148
Operating Income-26,508-28,200
 
Operating Expense (+$)
Research Development20,777
Selling General Administrative9,679
Selling And Marketing Expenses-
Operating Expense32,14830,456
 
Net Interest Income (+$)
Interest Income1,248
Interest Expense-115
Other Finance Cost-158
Net Interest Income975
 
Pretax Income (+$)
Operating Income-26,508
Net Interest Income975
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-25,987-26,054
EBIT - interestExpense = -115
-23,879
-23,764
Interest Expense115
Earnings Before Interest and Taxes (EBIT)--25,872
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-25,987
Tax Provision--33
Net Income From Continuing Ops-25,954-25,954
Net Income-23,879
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-454-975
 

Technical Analysis of Evogene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Evogene. The general trend of Evogene is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Evogene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Evogene.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 259.20 < 263.20 < 268.10.

The bearish price targets are: 208.00 > 190.00 > 189.30.

Tweet this
Evogene Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Evogene. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Evogene Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Evogene. The current macd is -11.86867113.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Evogene price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Evogene. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Evogene price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Evogene Daily Moving Average Convergence/Divergence (MACD) ChartEvogene Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Evogene. The current adx is 25.94.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Evogene shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Evogene Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Evogene. The current sar is 266.08.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Evogene Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Evogene. The current rsi is 42.87. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Evogene Daily Relative Strength Index (RSI) ChartEvogene Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Evogene. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Evogene price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Evogene Daily Stochastic Oscillator ChartEvogene Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Evogene. The current cci is -105.54491354.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Evogene Daily Commodity Channel Index (CCI) ChartEvogene Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Evogene. The current cmo is -10.93810709.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Evogene Daily Chande Momentum Oscillator (CMO) ChartEvogene Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Evogene. The current willr is -48.97959184.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Evogene is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Evogene Daily Williams %R ChartEvogene Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Evogene.

Evogene Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Evogene. The current atr is 13.00.

Evogene Daily Average True Range (ATR) ChartEvogene Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Evogene. The current obv is 2,529,755.

Evogene Daily On-Balance Volume (OBV) ChartEvogene Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Evogene. The current mfi is 43.99.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Evogene Daily Money Flow Index (MFI) ChartEvogene Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Evogene.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-31MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Evogene Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Evogene based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.865
Ma 20Greater thanMa 50273.075
Ma 50Greater thanMa 100291.384
Ma 100Greater thanMa 200294.045
OpenGreater thanClose246.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Evogene with someone you think should read this too:
  • Are you bullish or bearish on Evogene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Evogene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Evogene

I send you an email if I find something interesting about Evogene.


Comments

How you think about this?

Leave a comment

Stay informed about Evogene.

Receive notifications about Evogene in your mailbox!